Cipla Of India Markets Generic of Bayer's Kidney Cancer Drug
This article was originally published in PharmAsia News
India's Cipla has launched at home a generic version of Nexavar (sorafenib) marketed by Germany's Bayer to treat kidney cancer
You may also be interested in...
Sharing "Schering" Link Gets Bayer And Cadila To Talk Joint Venture; Deal Spanning Market To Manufacturing Likely In Final Stages
MUMBAI - Germany-headquartered agrichemicals-to-healthcare behemoth Bayer is talking to India's Cadila Healthcare to form an equal stake joint venture that will revolve around selling its own branded and generic products as well as contracting out a significant part of its manufacturing requirements
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.